DementiaNCT07313137
Antiplatelet Use in Dementia Subtypes
An observational study of Dementia and Dementia Disorder, run by Gulhane Training and Research Hospital.
Trial summary
This population-based retrospective cohort study aimed to evaluate the appropriateness of antiplatelet therapy use among older adults with all-cause dementia and across different dementia subtypes. Read more about this study
- Who is it for?
- Ages 65 years and older
- Conditions the study is for
- Dementia, Dementia Disorder
- How many people
- 683 participants
- Where
- No sites listed yet
- Study dates
- Dec 2016to Mar 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 years and older
- All sexes
- No healthy volunteers
- Older adult
Study population: The study population consists of older adults aged 65 years and older with a diagnosis of dementia who were evaluated in a tertiary-level geriatric outpatient clinic.
Who may be able to join
- Age 65 years and older.
- Diagnosis of dementia based on internationally accepted diagnostic criteria.
- Evaluation at a tertiary-level geriatric outpatient clinic.
Who cannot join
- Patients with incomplete or inaccessible medical records.
- Individuals with missing data on antiplatelet therapy use.
About this study
Official title: Antiplatelet Use in All-Cause Dementia and Dementia Subtypes Among Older Adults: A Population-Based Cohort Study
This population-based retrospective cohort study aimed to evaluate the appropriateness of antiplatelet therapy use among older adults with all-cause dementia and across different dementia subtypes. Medical records of patients aged 65 years and older who were evaluated at a tertiary-level geriatric outpatient clinic were reviewed. Dementia subtypes were classified according to internationally accepted diagnostic criteria. Patterns of antiplatelet use were assessed in accordance with current guideline recommendations. The study sought to determine the appropriateness of antiplatelet use across dementia subtypes and to describe real-world prescribing practices in this population.
- Conditions
- Dementia, Dementia Disorder
- Keywords
- Antiplatelet therapy, Older adults, Dementia subtypes
- Medical subject headings
- Dementia, Alzheimer Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Dementia cohort | This cohort includes older adults aged 65 years and older diagnosed with dementia who were evaluated in a tertiary geriatric outpatient clinic. No intervention was assigned, as this is a retrospective observational study. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Appropriateness of antiplatelet therapy use
Assessment of the appropriateness of antiplatelet therapy use according to current guideline recommendations among older adults with dementia.
Measured: At baseline (first geriatric outpatient clinic visit)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Dec 2025
- Study startDec 2016
- Primary completionMar 2025
- Study completionMar 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for DementiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 683 participants (actual)
Sponsor and investigators
- Lead sponsor
- Gulhane Training and Research Hospital
- Sponsor type
- Other government
- Responsible party
- Principal investigator, ZEHRA SARIKAYA DEMIRBAS, Gulhane Training and Research Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07313137
- Sponsor's protocol ID
- GTRH-ANTIPL-DEM-01
- Status last verified
- Dec 2025
- First submitted
- 17 Dec 2025
- Last updated
- 31 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 31 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Antiplatelet Use in All-Cause Dementia and Dementia Subtypes Among Older Adults: A Population-Based Cohort Study
- ClinicalTrials.gov ID
- NCT07313137
- Acronym / sponsor ID
- GTRH-ANTIPL-DEM-01
- Conditions
- Dementia, Dementia Disorder
- Keywords
- Antiplatelet therapy, Older adults, Dementia subtypes
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 683 participants (actual)
- Lead sponsor
- Gulhane Training and Research HospitalOther government
- Study start
- Dec 2016 (actual)
- Primary completion
- Mar 2025 (actual)
- Study completion
- Mar 2025 (actual)
- First posted
- 31 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This population-based retrospective cohort study aimed to evaluate the appropriateness of antiplatelet therapy use among older adults with all-cause dementia and across different dementia subtypes. Medical records of patients aged 65 years and older who were evaluated at a tertiary-level geriatric outpatient clinic were reviewed. Dementia subtypes were classified according to internationally accepted diagnostic criteria. Patterns of antiplatelet use were assessed in accordance with current guideline recommendations. The study sought to determine the appropriateness of antiplatelet use across dementia subtypes and to describe real-world prescribing practices in this population.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Dementia cohort | – | –This cohort includes older adults aged 65 years and older diagnosed with dementia who were evaluated in a tertiary geriatric outpatient clinic. No intervention was assigned, as this is a retrospective observational study. |
Who may qualify
- Ages
- 65 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
- Study population
- The study population consists of older adults aged 65 years and older with a diagnosis of dementia who were evaluated in a tertiary-level geriatric outpatient clinic.
Key inclusion criteria (3 listed)
- Age 65 years and older.
- Diagnosis of dementia based on internationally accepted diagnostic criteria.
- Evaluation at a tertiary-level geriatric outpatient clinic.
Key exclusion criteria (2 listed)
- Patients with incomplete or inaccessible medical records.
- Individuals with missing data on antiplatelet therapy use.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Appropriateness of antiplatelet therapy use
Time frame: At baseline (first geriatric outpatient clinic visit)
Assessment of the appropriateness of antiplatelet therapy use according to current guideline recommendations among older adults with dementia.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Dec 2025.
- Individual participant dataSharing planned: No
Related trials for Dementia
RecruitingObservational study
PET Imaging in the Baltimore Longitudinal Study of Aging (BLSA)
Aging
RecruitingPhase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
Alzheimer's Disease
Recruiting
Effects of Doll Therapy on Apathy and Activities of Daily Living Initiation Deficits in Older Adults With Dementia
Dementia
RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
Active, not recruiting
Effectiveness of Strength-based Intervention for Elderly With Dementia Living in the Community
Dementia, Mild Cognitive Impairment
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Dementia and Dementia Disorder, run by Gulhane Training and Research Hospital.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 31 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Appropriateness of antiplatelet therapy use (time frame: At baseline (first geriatric outpatient clinic visit)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Dec 2025.